What is Solid Biosciences Inc.'s R&D?

Solid Biosciences Inc. (SLDB) reported R&D of $46.14M in Q1 2026.

How has Solid Biosciences Inc.'s R&D changed year-over-year?

Solid Biosciences Inc.'s R&D increased by 49.3% year-over-year, from $30.91M to $46.14M.

What is the long-term trend for Solid Biosciences Inc.'s R&D?

Over 4 years (2021 to 2025), Solid Biosciences Inc.'s R&D has grown at a 24.3% compound annual growth rate (CAGR), from $58.74M to $140.33M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Solid Biosciences Inc. SLDB R&D

R&D at other companies

BiogenBIIB

$539M+24.2%

Neurocrine BiosciencesNBIX

$296.2M+12.5%

InsmedINSM

$209.49M+37.3%

Dyne Therapeutics, Inc.DYN

$100.89M-5.2%

Taysha Gene Therapies, Inc.TSHA

$33.81M+117%

Edgewise Therapeutics, Inc.EWTX

$42.65M+16.0%

Segments

By product

See full

SGT003$22.94M+150%

External General And Administrative Expense$19.47M-3.2%

Internal Research And Development Expense$9.15M+33.7%

SGT501$1.41M-68.5%

Other financials

Income statement

See full

Revenue$2.0M-40.6%

Operating income-$57.3M-43.1%

Net income-$56.7M-44.4%

EPS (diluted)-$0.52+11.9%

Balance sheet

See full

Cash & equivalents$297.1M+41.1%

Total debt$20.7M-12.5%

Total equity$374.1M+27.1%

Total assets$422.9M+23.0%

Cash flow

See full

Operating cash flow-$47.2M-48.3%

CapEx$165.0K+31.0%

Free cash flow-$47.4M-48.2%

Valuation

See full

Market cap$872.26M+135%

Enterprise value$595.83M+223%

P/S107.8×-9.9×

Profitability

See full

Operating margin-1,315.2%-4,060pp

Net margin-1,062.3%-251,151pp

FCF margin-1,247.7%-9,569pp

Returns & leverage

See full

Return on equity-57.4%+2.2pp

Debt / equity0.1×0.0×

Current ratio13.1×+2.2×

Where this comes from

Reported directly by Solid Biosciences Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Solid Biosciences Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Solid Biosciences Inc.'s r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Solid Biosciences Inc.'s R&D?: Solid Biosciences Inc. (SLDB) reported R&D of $46.14M in Q1 2026.
How has Solid Biosciences Inc.'s R&D changed year-over-year?: Solid Biosciences Inc.'s R&D increased by 49.3% year-over-year, from $30.91M to $46.14M.
What is the long-term trend for Solid Biosciences Inc.'s R&D?: Over 4 years (2021 to 2025), Solid Biosciences Inc.'s R&D has grown at a 24.3% compound annual growth rate (CAGR), from $58.74M to $140.33M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.